Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05241470
Other study ID # ST100-001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 17, 2021
Est. completion date October 11, 2021

Study information

Verified date February 2024
Source Stuart Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to compare the safety and efficacy of two different concentrations of ST-100 Ophthalmic Solution to placebo (vehicle) for the treatment of the signs and symptoms of dry eye.


Description:

This is a Phase 2, multi-center, double-masked, randomized, placebo-controlled clinical study. Subjects will be randomized to one of the following treatment arms at Visit 2 (Day 1): - Low dose ST-100 Ophthalmic Solution: 1 drop twice daily (BID) in each eye - High dose ST-100 Ophthalmic Solution: 1 drop BID in each eye - Placebo Ophthalmic Solution (Vehicle): 1 drop BID in each eye Approximately 150 subjects will be randomly assigned to one of the three groups (1:1:1) to receive either ST-100 Ophthalmic Solution or placebo solution as topical ophthalmic drops administered bilaterally BID for 4 weeks. Subjects, Sponsor, Contract Research Organization (CRO), and site personnel will be masked to treatment assignment. The clinical hypotheses for this study is that low dose and high dose ST-100 Ophthalmic Solution twice daily (BID) is superior to its vehicle (BID) for the primary endpoints of signs and symptoms of dry eye.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date October 11, 2021
Est. primary completion date October 11, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Be at least 18 years of age; - Provide written informed consent; - Have a subject reported history of dry eye; - Have a history of use of eye drops for dry eye symptoms; - Have symptoms of dry eye as determined by Ocular Discomfort & 4-symptom questionnaire; - Have a Schirmer's Test score of = 10 mm and = 1 mm; - Have conjunctival redness; - Have corneal fluorescein staining; - Have lissamine green conjunctival staining; - Have signs and symptoms responses to Controlled Adverse Environment (CAE®); Exclusion Criteria: - Have any clinically significant slit lamp findings; - Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation ; - Have worn contact lenses; - Have used any eye drops; - Have previously had laser-assisted in situ keratomileusis (LASIK) surgery - Have used Restasis, Xiidra, or Cequa ophthalmic solutions - Have any planned ocular and/or lid surgeries or any ocular surgery; - Have used, are using or anticipate using permanent or temporary punctal plugs during the study; - Be currently taking any topical ophthalmic prescription; - Be currently taking or have taken Omega-3 supplements; - Be unable to read an eye chart; - Be a woman who is pregnant, nursing, or planning a pregnancy; - Be unwilling to submit a urine pregnancy test (or early termination visit) if of childbearing potential; - Be a woman of childbearing potential who is not using an acceptable means of birth control; - Have a known allergy and/or sensitivity to the test article or its components; - Have a condition or be in a situation that the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study; - Be currently enrolled in an investigational drug or device study or have used an investigational drug or device; - Be currently using any medication known to cause ocular drying that is not used on a stable dosing regimen; - Have a known history of meibomian gland procedures (e.g., LipiFlow, LPI, probing, etc.); - Be unable or unwilling to follow instructions, including participation in all study assessments and visits.

Study Design


Intervention

Drug:
ST-100 Ophthalmic Solution
One drop in each eye twice a day
Placebo Ophthalmic Solution
One drop in each eye twice a day

Locations

Country Name City State
United States Andover Eye Associates Andover Massachusetts
United States Total Eye Care, P.A. Memphis Tennessee
United States Andover Eye Associates - Raynham Raynham Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Stuart Therapeutics, Inc. ORA, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline of Total Corneal Fluorescein Staining (Ora Calibra® Scale) in the Study Eye at Visit 7 (Day 29) Pre-Controlled Adverse Environment (Pre-CAE) The fluorescein staining is graded with the Ora Calibra® Corneal and Conjunctival Staining Scale. The scale is used to evaluate 3 corneal regions. Staining in each region is graded 0 to 4 where 0 means no staining, and 4 means worst staining. Higher score indicates more staining. The scoring reported ranges from 0-12. Mean change from baseline was calculated. Visit 2 (Day 1) to Visit 7 (Day 29)
Primary Change From Baseline of Ocular Discomfort in the Study Eye at Visit 7 (Day 29) Pre-CAE Ocular Discomfort Scale is graded using the Ora Calibra Ocular Discomfort Scale (ODS). The scale ranges from 0 means no discomfort to 4 means worst discomfort. Higher score indicates more discomfort. Visit 2 (Day 1) to Visit 7 (Day 29)
Secondary Unanesthetized Schirmer's Responder Rate The Schirmer's test strip is placed in the lower temporal lid margin of each eye. After 5 minutes, the test strip is removed and the length of the moistened area will be recorded in millimeters (mm) for each eye. The percentage of responders who had = 10 mm increase from baseline in study eye in unanesthetized Schirmer's test was recorded. Visit 7 (Day 29), Pre-CAE
Secondary Change From Baseline of Best-Corrected Visual Acuity (ETDRS) - logMAR (Fellow Eye) at Visit 3 (Day 2) LogMAR visual acuity (VA) is assessed using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The last line in which a letter is read correctly will be taken as the base logMAR reading. To this value will be added the number "N x 0.02" where 'N' represents the total number of letters missed up to and included in the last line read. This total sum represents the logMAR VA for that eye. Visit 3 (Day 2)
Secondary Change From Baseline to Visit 4 (Day 4) in Ocular Surface Disease Index (Blurred Vision) Ocular Surface Disease Index (OSDI) Questions 4: Have you experienced blurred vision during the last week? on 0-4 Scale where 4 is the worst at pre-CAE® Visit 4 (Day 4), Non-CAE
Secondary Change From Baseline to Visit 6 (Day 15) in Ocular Surface Disease Index (Pain) Ocular Surface Disease Index (OSDI) Questions 3: Have you experienced painful or sore eyes during the last week? on 0-4 Scale where 4 is the worst at pre-CAE® Visit 6 (Day 15) Pre-CAE
Secondary Change From Baseline in Ocular Discomfort Assessed by 4-Symptom Questionnaire The Ora Calibra® Ocular Discomfort & 4-Symptom Questionnaire is used, which includes rating of the severity of 5 symptoms: ocular discomfort, burning, dryness, grittiness, and stinging. Each symptom rating ranges from 0 to 5, where 0 = None and 5 = Worst. Higher score means worse symptom. Min score = 0, max score = 25. Visit 6 (Day 15) Pre-CAE
See also
  Status Clinical Trial Phase
Completed NCT03216096 - Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease Phase 1
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT04656197 - The Ocular Microbiome in Patients With Dry Eye Disease
Completed NCT05031806 - Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease Phase 1
Completed NCT03688802 - Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation Phase 2
Completed NCT05213156 - Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease Phase 4
Completed NCT04548427 - Study to Evaluate the Efficacy and Safety of CKD-352 Phase 3
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02254265 - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Phase 2/Phase 3
Completed NCT00395759 - The Visual Effect of an Investigational Artificial Tear in the Tear Layer. N/A
Completed NCT00680108 - A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution Phase 2
Recruiting NCT06064071 - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD N/A
Completed NCT04139122 - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease Phase 1/Phase 2
Not yet recruiting NCT06375343 - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® Phase 1
Completed NCT01468168 - A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients Phase 2
Completed NCT01014078 - A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Phase 4
Completed NCT00799682 - Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® Phase 4
Completed NCT05082974 - Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK) Phase 3
Recruiting NCT06146881 - Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia Phase 2
Completed NCT03292809 - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) Phase 2/Phase 3